Convergent effects of synthetic glucocorticoid dexamethasone and amyloid beta in human olfactory neurosphere‐derived cells
Zane Farnum,Radhika Mani,Aidan Bindoff,Richard Wilson,Adoni Fiotakis,Jessica Stephens,Ellie Cho,Alan Mackay‐Sim,Duncan Sinclair
DOI: https://doi.org/10.1111/jnc.16263
2024-11-26
Journal of Neurochemistry
Abstract:Life stress increases the risk of Alzheimer's disease but the mechanisms underlying this are unclear. To model the effects of life stress on the brain in the lead‐up to Alzheimer's disease, we treated human brain‐like cells from the olfactory mucosa with dexamethasone (a synthetic analogue of the stress hormone cortisol) and amyloid beta (Aβ; a hallmark of early brain changes in Alzheimer's disease). Dexamethasone and Aβ had overlapping effects on cells‐ dexamethasone counteracted some intracellular effects of soluble Aβ40 and exacerbated others. This suggests that stress hormones may have both beneficial and detrimental effects in the brain in Alzheimer's disease. Stressful life events and glucocorticoid (stress) hormones appear to increase the risk of Alzheimer's disease and hasten its progression, but the reasons for this remain unclear. One potential explanation is that when amyloid β (Aβ) pathology is accumulating in the preclinical disease stage, glucocorticoid receptor signalling during stressful events exacerbates cellular dysfunction caused by Aβ. Alternatively, Aβ may disrupt glucocorticoid receptor signalling. To explore these possibilities, we investigated whether the synthetic glucocorticoid dexamethasone and Aβ have overlapping effects on the cellular proteome and whether Aβ influences canonical glucocorticoid receptor function. Human olfactory neurosphere‐derived (ONS) cells, collected from the olfactory mucosa of six adult donors, were treated with soluble Aβ40 or Aβ42 followed by dexamethasone. Proteins were quantified by mass spectrometry. After 32 h treatment, Aβ40 and Aβ42 both induced profound changes in innate immunity‐related proteins. After 72 h, Aβ42 formed widespread aggregates and induced few proteomic changes, whereas Aβ40 remained soluble and altered expression of mitochondrial and innate immunity‐related proteins. ONS cells revealed overlapping impacts of Aβ40 and dexamethasone, with 23 proteins altered by both treatments. For 16 proteins (including eight mitochondrial proteins) dexamethasone counteracted the effects of Aβ40. For example, caspase 4 and methylmalonate‐semialdehyde dehydrogenase were increased by Aβ40 and decreased by dexamethasone. Consistent with this finding, Aβ40 increased, but dexamethasone decreased, ONS cell proliferation. For seven proteins, including superoxide dismutase [Mn] mitochondrial, dexamethasone exacerbated the effects of Aβ40. For some proteins, including complement C3, the effects of dexamethasone differed depending on whether Aβ40 was present or absent. Neither Aβ species influenced glucocorticoid receptor nuclear translocation. Overall, this study revealed that glucocorticoid receptor signalling modifies the intracellular effects of Aß40, counteracting some effects and exacerbating others. It suggests that cellular mechanisms through which glucocorticoid receptor signalling influences Alzheimer's disease risk/progression are complex and determined by the balance of beneficial and detrimental glucocorticoid effects.
biochemistry & molecular biology,neurosciences